Beltrae Partners

Beltrae Partners Limited is an independent corporate finance advisory firm founded in 2003, with offices in Belfast and Dublin. The firm specializes in private equity and property investments, focusing on European companies. Beltrae Partners aims to provide strategic financial advisory services while also engaging in investment activities, leveraging its expertise to support the growth and development of its portfolio companies.

James Mairs

Co-Founder, Shareholder, Investor and Director

2 past transactions

Neurovalens

Series A in 2019
Neurovalens Limited is a company based in Ballymena, United Kingdom, that specializes in the development of medical devices grounded in neuroscience, bioscience, and neurophysiology. Founded in 2013, the company focuses on creating non-invasive neurostimulation products to address significant health challenges, particularly obesity. Notable products include Stimu Slim and Modius, which are electronic headsets designed to promote weight loss through transdermal activation of brainstem and hypothalamic functions. These devices aim to enhance autonomic function and circadian regulation, offering healthcare providers drug-free alternatives to improve patient health outcomes. Neurovalens has also received support from Invest NI as part of the European Union’s Investment for Growth and Jobs Programme, which will facilitate research and development to enhance the company's competitiveness.

Neurovalens

Seed Round in 2017
Neurovalens Limited is a company based in Ballymena, United Kingdom, that specializes in the development of medical devices grounded in neuroscience, bioscience, and neurophysiology. Founded in 2013, the company focuses on creating non-invasive neurostimulation products to address significant health challenges, particularly obesity. Notable products include Stimu Slim and Modius, which are electronic headsets designed to promote weight loss through transdermal activation of brainstem and hypothalamic functions. These devices aim to enhance autonomic function and circadian regulation, offering healthcare providers drug-free alternatives to improve patient health outcomes. Neurovalens has also received support from Invest NI as part of the European Union’s Investment for Growth and Jobs Programme, which will facilitate research and development to enhance the company's competitiveness.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.